Contrast-enhanced MRI and CT in evaluating treatment response for recurrent endometrial cancer: a retrospective case-control study.

IF 3.6 3区 医学 Q2 ONCOLOGY
American journal of cancer research Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.62347/TUED9082
Yan Chen, Xueling Wang
{"title":"Contrast-enhanced MRI and CT in evaluating treatment response for recurrent endometrial cancer: a retrospective case-control study.","authors":"Yan Chen, Xueling Wang","doi":"10.62347/TUED9082","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To compare the diagnostic performance of contrast-enhanced magnetic resonance imaging (CE-MRI) and computed tomography (CT) in evaluating treatment response for recurrent endometrial cancer (EC), and to assess the added value of integrating imaging findings with biomarker data.</p><p><strong>Methods: </strong>This retrospective case-control study included 217 patients with recurrent EC treated between January 2020 and December 2023. Patients were divided into response (n = 102) and non-response (n = 115) based on Response Evaluation Criteria in Solid Tumors (RECIST) (1.1). An internal validation cohort (n = 142) and an external cohort (n = 168) were also analyzed. Preoperative CE-MRI and CT scans were reviewed by experienced radiologists. Biomarker positivity rates - including estrogen receptor (ER), progesterone receptor (PR), cancer antigen 125 (CA125), cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and ovarian cancer-related protein 1 (OVX1), were assessed. Multivariate logistic regression and receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic performance, and an integrated model combining imaging and biomarkers was developed.</p><p><strong>Results: </strong>CE-MRI achieved an AUC of 0.864, sensitivity of 78.3%, and specificity of 86.3%, while CT showed an AUC of 0.854, sensitivity of 81.2%, and specificity of 83.4%. The integrated model improved performance with an AUC of 0.889, sensitivity of 94.3%, and specificity of 81.2%. Internal and external validation models yielded AUCs of 0.859 and 0.918, respectively.</p><p><strong>Conclusions: </strong>Both CE-MRI and CT are effective in assessing treatment response, with CE-MRI offering slightly superior specificity. Integration of imaging and biomarker data significantly enhances diagnostic accuracy, supporting its potential in optimizing individualized treatment strategies for recurrent EC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 5","pages":"2077-2096"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163448/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/TUED9082","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To compare the diagnostic performance of contrast-enhanced magnetic resonance imaging (CE-MRI) and computed tomography (CT) in evaluating treatment response for recurrent endometrial cancer (EC), and to assess the added value of integrating imaging findings with biomarker data.

Methods: This retrospective case-control study included 217 patients with recurrent EC treated between January 2020 and December 2023. Patients were divided into response (n = 102) and non-response (n = 115) based on Response Evaluation Criteria in Solid Tumors (RECIST) (1.1). An internal validation cohort (n = 142) and an external cohort (n = 168) were also analyzed. Preoperative CE-MRI and CT scans were reviewed by experienced radiologists. Biomarker positivity rates - including estrogen receptor (ER), progesterone receptor (PR), cancer antigen 125 (CA125), cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and ovarian cancer-related protein 1 (OVX1), were assessed. Multivariate logistic regression and receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic performance, and an integrated model combining imaging and biomarkers was developed.

Results: CE-MRI achieved an AUC of 0.864, sensitivity of 78.3%, and specificity of 86.3%, while CT showed an AUC of 0.854, sensitivity of 81.2%, and specificity of 83.4%. The integrated model improved performance with an AUC of 0.889, sensitivity of 94.3%, and specificity of 81.2%. Internal and external validation models yielded AUCs of 0.859 and 0.918, respectively.

Conclusions: Both CE-MRI and CT are effective in assessing treatment response, with CE-MRI offering slightly superior specificity. Integration of imaging and biomarker data significantly enhances diagnostic accuracy, supporting its potential in optimizing individualized treatment strategies for recurrent EC.

对比增强MRI和CT评价复发性子宫内膜癌治疗效果:一项回顾性病例对照研究。
目的:比较对比增强磁共振成像(CE-MRI)和计算机断层扫描(CT)在评估复发性子宫内膜癌(EC)治疗反应中的诊断性能,并评估将成像结果与生物标志物数据相结合的附加价值。方法:本回顾性病例对照研究纳入了2020年1月至2023年12月期间接受治疗的217例复发性EC患者。根据实体瘤应答评价标准(RECIST)(1.1)将患者分为应答(n = 102)和无应答(n = 115)两组。内部验证队列(n = 142)和外部验证队列(n = 168)也进行了分析。术前CE-MRI和CT扫描由经验丰富的放射科医生检查。评估生物标志物阳性率,包括雌激素受体(ER)、孕激素受体(PR)、癌抗原125 (CA125)、癌抗原19-9 (CA19-9)、癌胚抗原(CEA)和卵巢癌相关蛋白1 (OVX1)。采用多变量logistic回归和受试者工作特征(ROC)分析来评估诊断效果,并建立了一个结合成像和生物标志物的综合模型。结果:CE-MRI AUC为0.864,敏感性78.3%,特异性86.3%;CT AUC为0.854,敏感性81.2%,特异性83.4%。综合模型的AUC为0.889,灵敏度为94.3%,特异性为81.2%,提高了诊断效果。内部和外部验证模型的auc分别为0.859和0.918。结论:CE-MRI和CT均能有效评估治疗反应,CE-MRI的特异性略优于CT。影像和生物标志物数据的整合显著提高了诊断的准确性,支持其在优化复发性EC的个体化治疗策略方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
3.80%
发文量
263
期刊介绍: The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信